| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9959995 | Journal of the American College of Cardiology | 2005 | 7 Pages |
Abstract
Eplerenone 25 mg/day significantly reduced all-cause mortality 30 days after randomization (when initiated at a mean of 7.3 days after AMI) in addition to conventional therapy in patients with an LVEF â¤40% and signs of heart failure. Based on its early survival benefit, eplerenone should be administered in the hospital after AMI.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Bertram (FACC), Harvey (FACC), Jose (FACC), Felipe MD, Mihai (FACC), Michael MD, Dirk J. (FACC), Faiez MD, Henry MD, Robin PhD, John MD, PhD, EPHESUS Investigators EPHESUS Investigators,